#1PI Industries Ltd. Investor Presentation Q3 FY24 Results Pi Inspired by Science 1#2AGENDA Pi Inspired by Science CDR India Siddharth Rangnekar [email protected] Nishid Solanki [email protected] Tel: +91 22 6645 1221/1209 Fax: +91 22 6645 1213 PI Industries Limited Rajnish Sarna [email protected] Manikantan Viswanathan [email protected] Tel: +91 124 6790000 Fax: +91 124 4081247 Consolidated Financial Performance CSM Exports • Domestic Agri Brands • Pharma Updates • Business Model and Strategy • ESG Credentials • CSR Update Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements," including those relating to general business plans and strategy of PI Industries Limited ("PIIL"), its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause the actual results to differ materially from those contemplated by the relevant forward-looking statements. This could also differ due to a number of other factors, including future changes or developments in PIIL's business, its competitive environment, its ability to implement its strategies and initiatives and respond to technological changes. This presentation does not constitute a prospectus, offering circular or offering memorandum or an offer, or a solicitation of any offer, to purchase or sell, any shares and should not be considered as a recommendation that any investor should subscribe for or purchase any of PIIL's shares. Neither this presentation nor any other documentation or information (or any part thereof) delivered or supplied under or in relation to the shares shall be deemed to constitute an offer of or an invitation by or on behalf of PIIL. This presentation should be read in conjunction with the financial statements included herein. PIIL, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this presentation, unless otherwise specified is only current as of the date of this presentation. PIIL assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this document, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. PIIL may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation may not be copied and disseminated in any manner. PIIL will not be in any way responsible for any action taken based on such forward-looking statements. THE INFORMATION PRESENTED HERE IS NOT AN OFFER OR SOLICITATION OF ANY OFFER TO PURCHASE OR SELL ANY EQUITY SHARES OR ANY OTHER SECURITY OF PI INDUSTRIES LTD. 2#3Growth momentum continues...vindicates differentiated business model and diversified product portfolio Pi Inspired by Science Revenue Figures in Rs. Million EBITDA PAT *Q3FY24 18,975 18% 5,550 34% 4,486 28% *YTM 9MFY24 59,248 20% 15,810 31% 13,120 38% Commercialised 4 new products in Exports and 5 in Domestic Agri Brands CSM Exports Order Book - USD ~1.7 billion Diversification in Pharma done, integration of CRO-CDMO-API platforms underway Trade working capital reduced from 90 days to 80 days 1st Indian company to get a new ISO approval "Pioxaniliprole" * Consolidated Financials 3#4New products commercialisation driving growth in Exports and Q3FY24 revenues Pi Inspired by Science ☐ Fig in Rs. Million Q3FY23 Q3FY24 % YOY Overall 18% Y-o-Y revenue growth ☐ Revenue 16,132 18,975 18% Gross Margin 47% 54% 640 bps Overheads 3,456 4,626 34% EBITDA 4,156 5,550 34% EBITDA as % of 26% 29% 348 bps Revenue Net Profit 3,518 4,486 28% 23% -6% 34% 28% Mn Mn 16,310 5,550 13,286 4,156 4,486 ■ 3,518 ☐ ☐ 13% growth in Agchem Exports driven by volume growth and newly commercialised products. Pharma contributed Exports revenue of Rs. 1,273 million i.e. ~10% of total Exports revenue growth. Domestic revenues were subdued with reduction of ~6% Y-o-Y due to delayed and erratic spread of monsoon although favourable product mix and improved working capital management helped contain financial impact. Gross Margin and EBITDA improved mainly on account of favorable product mix, operating leverage and one-time impact of recovery of theft material contributing ~300 bps improvement in EBITDA. Overheads increase mainly attributable to the newly acquired Pharma businesses hence not comparable. The Board has considered interim dividend for FY23-24 of Rs 6.00 per share Exports Q3FY23 2,8462,665 Domestic Q3FY24 EBITDA Q3FY23 PAT Q3FY24 1 Pharma: Pl Health Sciences Ltd. ("PIHSL") Consolidated including overseas subsidiaries 4#5Robust performance in 9MFY24 despite challenging times Testament to resilient business model and execution capabilities Fig in Rs. Million 9MFY23 9MFY24 % YOY Revenue 49,264 59,248 20% Gross Margin 45% 49% 337 bps Overheads 10,383 13,177 27% EBITDA 12,049 15,810 31% EBITDA as % of 24% 27% 223 bps Revenue Net Profit 9,490 13,120 38% 31% 38% 29% -7% Mn Mn 15,810 12,049 37,490 48,269 Exports 9MFY23 11,774 10,979 Domestic 9MFY24 EBITDA 9MFY23 13,120 9,490 PAT 9MFY24 1 Pharma: Pl Health Sciences Ltd. ("PIHSL") Consolidated including overseas subsidiaries Pi Inspired by Science Overall 20% Y-o-Y revenue growth 22% growth in Agchem Exports over a high base mainly on account of scale-up of existing products and introduction of 4 new products. Growth comprises volume growth of ~21% and ~1% from price, currency and favourable product mix. Newly acquired Pharma¹ contributed to remaining Exports revenue of Rs. 2,434 million i.e. ~7% of total Exports revenue growth. Domestic segment remained subdued due to erratic monsoon and El Niño conditions which led to long dry spells impacting insecticide and herbicide sales in certain geographies. However focused efforts were made to improve product mix by launching new brands and improving working capital efficiency. Overheads increase attributable to the newly acquired Pharma businesses (~13%) and balance (~14%) to scale-up of Exports and promotion expenses for the launch of the new products. Overall favorable product mix and significant increase in operating leverage reflected in improvement in EBITDA margin to 31%. Net profit improved by 38% Y-o-Y attributable to EBITDA growth, low ETR. Cash flow from operating activities increased 16% to Rs. 11,561 million and Rs 12,889 million excluding Pharma¹ (9MFY23 Rs. 9,951 million). 5#6Solid Balance Sheet: result of sustained internal accruals, efficient NWC management and disciplined capital allocation Fig in Rs. Million Shareholders Fund Pi Inspired by Science - Highlights of 9MFY24 Net fixed asset increase by Rs. 7,821 million Y-o-Y. Total capex for 9MFY24 is Rs. 9,001 million including Pharma¹ acquired assets of Rs 4,972 million. The capex excluding this addition is Rs. 4,029 million (9MFY23 Rs. 2,585 million). Increase in Other assets includes long term fixed deposits of Rs. 658 million. Trade working capital in terms of Days of Sales improved to 80 days as on 31-Dec-23 vs. 90 days as on 31-Dec-22. Inventory levels of Rs. 12,743 million and Rs. 11,878 million excluding Pharma¹, reduced in terms of Days of Sales to approx. 59 days to vs. 81 days as on 31-Dec-22. Surplus cash net of debt is Rs. 32,926 million. Dec-23 84,508 Mar-23 71,985 Dec-22 69,716 ◉ Non Current Liabilities 3,082 994 2,233 Long term borrowings 697 1,056 Other long term liabilities 2,385 994 1,077 Current liabilities 16,521 11,818 14,209 Short term borrowings 1,004 1,089 Trade payables 10,476 8,380 9,459 Other current liabilities 5,041 3,438 3,661 Total 1,04,111 84,797 86,158 Non Current Asset 39,131 28,174 27,393 Net Fixed Asset 33,633 26,551 25,812 Goodwill 3,618 828 828 Non current investments 872 313 301 Other assets 1,009 482 452 Current Assets 64,980 56,623 58,765 Inventories 12,743 13,976 14,517 Trade receivables Cash, Bank & Investments 15,099 8,381 11,156 34,045 32,272 31,019 Other assets 3,092 1,994 2,073 Total 1,04,111 84,797 86,158 Key Ratios (%) Annualised Net Sales to Trade Working Capital 4.55 4.64 4.05 Debt/Equity Ratio 0.02 Nil 0.03 Net Sales to Net Fixed Assets 2.35 2.45 2.54 2 ROCE 31.7% 34.6% 31.9% 1 Pharma: Pl Health Sciences Ltd. ("PIHSL") Consolidated including overseas subsidiaries 2 ROCE computed excluding Cash, Bank & Investments 6#7PI Health Sciences: Initial development spend reflecting in the financials... Integration of CRO-CDMO-API platforms underway Fig in Rs. Million Revenue 65 Gross Margin 54% Q3FY24 Ind AS Q3FY24 Proforma Adjustment Reported 1,207 1,273 51% 9MFY24 2,839 Ind AS Proforma Adjustment (405) 9MFY24 Reported ■ State-of-the-art research centre in Hyderabad 2,434 62% 58% Overheads 650 650 1,650 1,650 EBITDA 1 3 4 118 (351) (233) EBITDA as % of Revenue 0% 0% 4% N.M. 9MFY24 Pi Inspired by Science ■ CMO for RSM and KSM and CRDO at Jaipur ■CRDO in Alabama, US ■ GMP Speciality API and CDMO plant at Lodi, Italy Aforesaid financials represent consolidated financials of PI Health Sciences Ltd. including acquired businesses of Archimica S.p.A., Therachem Medilab, PIHS Hyderabad etc. ■ Proforma EBITDA for 9MFY24, before development spend of ~Rs. 350 million, works out to ~16%. ■ Inventory of Rs. 865 million reduced from Rs. 1,172 million as on 30-Sep-23. ■ Capex 9MFY24 of Rs. 1,008 million. Few areas of integration activities Strategic ■In-depth mapping of global CRDO-CDMO value chain ■ Areas of strategic focus and differentiation for PIHS ■ SAP integration across all sites IT ■ Seamless and common platform for email, processes ■Integrated organisation structure HR ■ Job bands and HR policies harmonisation SCM ■ Procurement and logistics processes digitized ■S & OP procedures standardised On path to build future growth engine for PI#8State-of-art Manufacturing Assets with continued thrust to adapt sustainable practices • Digital Edge Adaptive Controls to optimize Yield, Quality, Energy & Throughput Sensor-based Data Capturing for KPI Monitoring in Utilities Key Material Issues SDG Alignment ICENCMIC CRENTH Economic Contribution to ICT innovation Economic Supply Chain Management, Product Safety and Quality Assurance DECENT WORK AND ECONOMIC GROWTH 12 RESPONSIBLE 12 AND PRODUCTION Environment - ANDRASTRUCT Emission control Environment - Energy management CLEAN DENY Environment - Materials AND COURTES 16 Environment - Water management AND SANTANTES Environment - Waste management SASTABLE CITES AND COMMENTS Pi Inspired by Science Key Highlights 6MFY24 15 fully automated Multipurpose Plants (MPPs) with Distributed Control system (DCS) spread across 5 locations 90% of raw material/packing material suppliers assessed for sustainable sourcing including their environmental impacts Continued reduction in intensity from carbon emissions Contribution of 4+% from renewable energy in the total electricity mix Increase in tons of input material recovered and reused ~40,000 KL water recycled through rain water harvesting & RO permeate Reduction in hazardous waste generation 8#9World-class R&D set-up delivering innovative and disruptive solutions Pi Inspired by Science State-of-the-art R&D Labs at Udaipur, Hyderabad, Jaipur, Lodi and Alabama 700+ Scientists & Researchers incl. 200+ Doctorates 155+ Patents filed 11 patents filed in 9MFY24 In-house library with a vast array of knowledge resources R&D A.M Agchem Labs Specialized department of IT experts focusing on advanced data management NABL ISO17025 Accredited and GLP certified Inauguration of the latest addition to our R&D facility (Udaipur) - pXRD (Powder X-ray Diffraction) that will help in identification and quantification of different Polymorphs. 50+ Products at different development stages ~50% of the New Enquiries from non-agchem space 4 New Products Commercialized in YTM FY24 1st Indian company to receive approval from International Organization for Standardization (ISO) for groundbreaking insecticide named "PIOXANILIPROLE" Pharma Labs#10Momentum of new Brand launches in Domestic market to continue.. 5 Innovative Brands launched in 9MFY24 Pi Inspired by Science CLARET® Unique combination of systemic and contact insecticide with dual action on BPH in Paddy INSECTICIDE CLARET Dintefuran 5%+ Ethion 50% EC 800- EKETSU pyribac Sodium 38 Chiorimuran E +385- 1255- Metsulfuron HERBICIDE EKETSUT 1st 3-way (mixture of 3 proven chemistries) Post Emergent Broad spectrum Rice Herbicide KADETTⓇ Seed treatment in Soybean & Groundnut to prevent diseases and provide Active Root Growth FUNGICIDE KADETT FUNGICIDE PIILIN FUN Poly DZinc Salt 5% Se FUNGICIDE PIILIN® Bio-fungicide for effective Powdery Mildew disease management in Grapes & Chilli with Novel Mode Of Action & MRL exemption AMINOGROW ACTIV™M Amino acid & Peptides product to enhance quality of fruit and lower flower drop BIOLOGICALS AMINOGROW ACTIV AMINO AC&PEPTIDES Robust pipeline of over 20 products under registration and development 10#11Most comprehensive innovative portfolio for all major crops HORTICULTURE CHILLI CORN BROFREYA SECTIN KEEFUN KITAZIN SNAILKILL OSHEEN AMINOGROW ULTRA ACTIV BROFREYA JUMBO FOSMITE SIMBAA SUKHEE Estion 50% EC Drofenilde 20% 0 AWKIRA DEFENSA VISMA TOMATOUGH BIOVITA ** CLUTCH SANIPEB SUKHEE Pb5% +Mt55% W Press P RICE NOMINEE GOLD SEAWEED HUMESOL LIBRA Hunc Acid% Fave% TAURUS Corse KEEFUN VISMA KITAZIN Ta 182% Py COSKO PIILIN BIOVITA SEAWEED CLUTCH SANIPEB Pyracletrobin 5% +Matram 56% WO HUMESOL TOMATOUGH COSKO C PIILIN Hum Add Fulvic Acid 1.5% AMINOGROW ACTIV SOYBEAN Pi Inspired by Science BIOVITA SEAWEED ELITE ДУЗЯТОЯВ COSKO KADETT FOSMITE BIOVITA Ethion 50 EC KIMBO AWKIRA DISTRUPTOR OSHEEN VIBRANT Ch COSKO LEGACEE COTTON Pomazine % WG Cleateturen 20. se Bpyribec Sodium 10% SC Corentrantipmale C.4% OR OSHEEN DINOACE PROVIDE ROKET HUMESOL ULTRA PB KNOT Humic Acid 18% WHEAT KITAZIN HEADER WAGON Londax Power PIMIX RODEO OSHEEN CLARET BIOVITA HUMESOL SHIELD EKETSU ULTRA Dr wo Detai Ethion SEAWEED Fulvic Acid 1.5% OSHEEN CLUTCH FOSMITE RODEO BIOVITA C0%CC Pyrackstrobin s Matiram 55% W SEAWEED AXBEY AWKIRA WICKET MELSA JEEV BIOVITA SEAWEED BUNKER Pendimethali 30% C SOLARO 11#12Enhancing farm productivity through farmer education and innovative solutions remains at the core of our offerings... 19 million acres 2 million farmer visits TREATED ACREAGE DEMAND GENERATION ACTIVITIES • Solutions for Cotton, Rice, Wheat, Corn, Soybean, Horticulture and Chilli INTEGRATED CROP SOLUTION APPROACH • Awkira™ Ka Hero campaign •Satkaar Campaign felicitating farmers • Eketsu™M Village Launches • DistruptorⓇ- XP Hai to Happy Hai • Badlav ki Boond-Mandi campaign INNOVATION IN PROMOTION नोमिनी गोल्ड सत्कार कार्यक्रम नोमिनी गोल्ड के संग, धान में झलके असली सोने का रंग. बरसों के साथ से मिली उन्नति की तेज रफ़्तार गर्व के साथ करें अपने साथियों का सत्कार! NO NEE P Industries welcomes t Retailers Training Programme 段 VIPEFINT VURFINT Whabent Pi Inspired by Science 12 122#13Outlook remains positive...on path to deliver guided growth for FY24 Pi Inspired by Science Domestic: Focus on portfolio diversification with high quality revenue CSM Export: Technology focused approach to drive incremental business Health Sciences: Building a differentiated play in Pharma CRDMO space Monsoon deficit in south and low reservoir levels Elevated inventory levels in the industry for row crop Agchem products and price pressure from generics to continue Integrated crop solution approach with focus on quality of revenue and efficient NWC management Continued scale up in demand of the newly commercialised products: to drive growth in next quarters Solid R&D pipeline of diversified portfolio of Agchem, electronic, imaging and other specialty chemicals - 4 to 5 products to be commercialized every year - ~30% from non-Agchem Capacity expansion in line with plan - to commission 2 plants in next 1-year Operating model, functional and IT integration of acquired companies nearing completion New business development efforts intensified Build-up of Hyderabad research center and staffing at full swing; soon getting commissioned Capex committed for upgrade of facilities and building cutting-edge capabilities at Lodi and Jaipur facilities Progressing on strategic initiatives in line with plan Strong pipeline of Biologicals and Biostimulant products at different stages of development • Actively evaluating a few inorganic growth opportunities Promising R&D leads progressing towards development phase 13#14An organisation that is committed to excellence in whatever it does... PI Pl the company "Outshines competitors in delivering business needs of the customers by unlocking value & fearlessly reinventing ourselves " known for over 2 decades to be the top wealth creator ... AA A Trusted brand & partnerships 50+ years of relationship with Japanese companies Zero conflicts till date Successful product brands & Services Ranked amongst Top 3 in the world in CSM 70+% revenue from patented products Science & Technology ESG The only fully integrated R&D with all disciplines under one roof- a global benchmark Rapid adoption of latest technologies ESG a way of life 95 percentile Industry Ranking S&P Global Corporate Sustainability Assessment for 2023 GOLD 2023 ecovadis Sustainability Rating Addressing emerging opportunities • Pi Inspired by Science Never a "me-too" player Establishing new frontiers of Agri, Horticulture, Biologicals, Health Sciences .. 14#15Multipronged strategy to sustain the growth momentum backed by multiple growth engines & aggressive M&A Pi Inspired by Science Market • Expansion • Creation • Segments . Operation excellence ⚫ Brands Organic Grow Smart Inorganic Value added Technology • Products Assets • • . Niche vertical with a future Pharma/Specialty chemical High growth application areas having synergy Disruptive technologies in chemistry & process engineering Inorganic Value creation Build Customer Intimacy Product & services IP De-risk & Create Deepening our technological capabilities to open new horizons • De-risk Manufacturing concentration • New formulation of existing products • Biological Digital Process • Chemistry • Information • Block Builders integration Process engineering • Decision tools ⚫ Flow Multiple Growth Engines / Levers - • CSM Technologies, patent cliff, process innovation • Domestic Marketing & Distribution - Product Pipeline • Biologicals Stream • Horticulture Specialist - Product pipeline, geographic expansion • . PI Health Science - CRO, CDMO, API to tap > $100 Bn market opportunity Research Product from CRE - Global partnership Prudent capital allocation to ensure the long-term shareholder value creation 15#16PI featured in the S&P Global Sustainability Yearbook 2024 Ranked among the best ESG rated companies globally... Environmental SDG Alignment Key Material Issues Key Highlights 6MFY24 Continued reduction in intensity from carbon emissions 13 Environment - Climate change - 15 7 4 МАРТ МИ AND HE 15 ON LAND 2 ZERS CLEAN WATER 6DATION -> . ->> COM -> Environment - Biodiversity and ecological conservation Environment - Emissions control Environment Energy management Environment - Soil Health Environment - Water management Environment - Waste management Developed 15 acres of green belt by converting barren land into farmland Captive Solar Power Project with an impressive capacity of 887 KWp. This cutting-edge venture spans across two strategically chosen sites, to power our operations and forge a greener future. Contribution of 4+% from renewable energy to total electricity consumption Reduction in hazardous waste generation ~40,000 KL water recycled through rain water harvesting & RO permeate ~17% reduction in landfill (hazardous) waste generation Social and Governance 90% of raw material/ packing material suppliers assessed for sustainable sourcing including their environmental impacts. • In YTMFY24, biologicals contributed 9.8% to the domestic agri brands revenues. YTM FY24 learning hours by the employees aggregating 80,000+ hours. • Access to top content of more than 10,000+ modules in addition to learning experience platform Percipio. • Launched Management Development Program in collaboration with IIM Udaipur. • 20+% of new joiners were campus hires from Tier-1 colleges. • Increased women's participation in leadership positions by 15+% over FY23 • PI funded not-for-profit blood bank in Ankleshwar, Gujarat benefited 5,500+ beneficiaries. Upgraded Anganwadi centers at Samoj, Jambusar Taluka, Gujarat benefiting 5,000+ children. Pi Inspired by Science S&P Global S&P Global Corporate Sustainability Assessment (CSA) ranking improved to 95th percentile Retained Ecovadis Gold medal in sustainability achievement 2023 with 98th percentile ranking GOLD 2023 ecovadis Sustainability Rating Launched revamped Environment Sustainable Procurement Policy Water Management Policy Environment Management Policy related policies in August 2023 . Occupational Health & Safety Management Policy Equal Employment Opportunity Policy https://www.piindustries.com/sustainability/ehs/ sustainable-procurement-policy/ • Transportation and Distribution Safety Policy 16#17People first: HR Snapshots Culture Capability Development • Continuing "PI Values Assessment" program to reinforce commitment to organizational values ⚫ POSH Training conducted in local languages to promote an inclusive and ethical workplace culture Continuing "PARIVARTAN" training program Higher Education Policy encouraging continuous professional development Talent Management Employee Connect Systematic evaluation of Management Trainees to assign them to assume greater responsibilities • Direct communication through various channels to drive deeper engagement and awareness Safety Awareness • Partnered with renowned institutions of IIT Madras and NITM to deliver specialized safety training for manufacturing workforce ⚫ 10,000+ hours dedicated to safety training, underscoring our unwavering commitment to workplace safety SPORTS Pi Inspired by Science Champions 17#18Our CSR efforts focused on community welfare & environment Foundatio VOORLEER 9316 2 925 • • • CSR policy directed towards inclusive development that creates value for the society, especially around our plant and farmers across the country Health & Hygiene Health & wellness support for rural communities Supporting communities in 64 villages in Swasthya Seva Program 21,000+ beneficiaries reached in Q3 6.65+ lakh beneficiaries reached so far Improving nutrition level of children suffering from malnutrition in 66 Aanganwadis ~7,000 adolescent children trained to improve health & well-being in Project Vriddhi ++ • • • • Women Empowerment Program running in 80 rural villages 5,400+ women smallholders directly benefitted in Q3. 7,000+ women smallholders impacted, which makes it ~28,000 people at a household level Financial access to 100% • ~25% income levels have increased through this program Pi Inspired by Science Environment Sustainability Promoting Sustainable Farming Practices & Biodiversity Conservation 7,200+ farmers reached covering 1,700 acres in Q3 in Sustainable Agriculture project ~7.8 lakh famers reached so far 1.74 trillion litres of water saved through Direct Seeding of Rice (DSR) ~30,000 trees planted for a significant positive impact on the environment Pi Foundation Education & Skill Development Introducing digital learning & smart classes in rural India Program is supporting 135 schools to improve learning outcomes of children 4,400+ students reached in Q3 • 630 ~63,000 students impacted so far 230 youth enrolled in Q3; 3,700+ youth have been skilled, 90% have got gainful employment Smart learning through project Digitalshala launched recently and will reach 100 schools 18#19Rewards and Recognition PI Industries Ltd. recognized as Dun & Bradstreet India's Top Value Creator 2023 - - Agro Chemicals dun&bradstreet INDIA'S VALUE CREATOR 2023 AGRO CHEMICALS ELLE DUSTICES IMI SB be 52 ट्रीय क्षा दिस 202 APEX INDIA FOUNDATION CERTIFICATE This certificate is preadly presented to M/s PI Industries Ltd. Udaipur R & D Sector Aas been declared wines of Apex India Occupational Health & Safety Award 2023 Gold Award KelpH P POSH AWARDS 2023 Top 25 Safest Workplaces in India Creating a SAFE WORKPLACE towards building an ESG-DRIVEN ENTERPRISE Pi Inspired by Science PI Industries Ltd. selected as one of the Top 25 Safest Workplaces in India by KelpHR Posh Awards 2023 INDIA'S BEST TRAILBLAZER CEO AGRO CHEMICAL Awarded to Mr. Mayank Singhal Vice Chairman & Managing Director, Pt Industries Ltd. Karkhana Suraksha Puraskar Award 2023 A testimony to the exceptional safety standards Pl consistently maintains PI Industries Ltd., Udaipur wins Gold Award in R&D Sector under the Apex India Occupational Health & Safety Award 2023 India's Best Trailblazer CEO - Agro Chemicals Awarded to Mr. Mayank Singhal by Corporate Leadership Awards 2024 19#20INT Reimagining a healthier planet! "Lead with science, technology and human ingenuity to create transformative solutions in life sciences" Courageous Think Bold, act with Integrity and be Accountable. 24 PI Internal Curious Question conventional wisdom, be Open-minded, Adaptable and Curious. Pi Inspired by Science Creative Differentiate, Collaborate, Experiment and Execute ideas at speed. Caring Be Transparent, build Trust, bring the best out of People and embrace Sustainability. Partner Centric First to identify & deliver on latent needs of our customers Science & Technology Driven Sustainable solutions by early adoption of cutting-edge science /technology Digital Edge Integrated digital solutions to gain competitive advantage People First Best opportunities for employees to learn & grow ESG Anchored ESG the way of Life ave 20#21Business model built on the principles of respect for IP and established relationships Domestic Brand Market Leading Agchem Distribution Company in India with leading market share in certain crops India's largest CRAMS Company with majority revenue from Patented Products Exports Market Pi Inspired by Science Leveraging our Pan India network, demonstrating brand building capabilities and experienced team to deliver in- licensed, branded generics & co-marketed products IN-LICENSING . • Introducing new products, partnering with global innovators Ensure longer product cycles by brand building Develop solutions for the Indian Ag-chem Industry with the partnership approach R&D Partnership SYNERGISTIC APPROACH Common Infrastructure Develop knowledge, products, processes and experience in different complex chemistries Cross-Selling Opportunities Leveraging on chemistry process research and manufacturing capabilities catering to Global Innovators; Partnering for IP Creation. Custom Synthesis & Manufacturing • Early stages of their life cycles • Complex Chemistries • Process development • IP Protection & Generation 3 Global locations ⚫ Japan for business development activities . State of the Art R&D facilities 500+ researchers and • To service its customers • 1 R&D Facility scientists • Accredited for GLP and 'Norms 4 Manufacturing Sites on OECD Principles' by NGCMA • Domestic Brand Distribution • 25 stock points 10,000+ distributors 80,000+ retail points China for Sourcing Germany for Knowledge Management • Consistent track record of financial performance Non conflicting business model... well respected by Global Innovators as Partners 21 ང་#22Thank You Pi Inspired by Science 22